Questions discussed in this category
This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.
The patient has no extraocular features of a spondyloarthropathy and is on methotrexate. No active eye disease for past 1 year.
Thrombophilia testing, including JAK2 is negative. When would you stop anticoagulation?
Are these toxicities expected to improve over time?
No active joint disease, patient on Hydroxychloroquine and Cimzia. Normal ESR/CRP.
Do you refer them to Ophthalmology? Have you had to switch patients off of Dupixent due to their ocular side effects?
2271516411205272075726172222120051149381582716309156881567015615142551244312421110548388
Papers discussed in this category
Ann Intern Med, 2020 Sep 22
Obstet Gynecol Surv,
Arthritis Rheum,
Int J Environ Res Public Health, 2021 Aug 01
N Engl J Med, 2021 Jun 23
BMC Rheumatol, 2021 Oct 01
Clin Ophthalmol, 2011 Oct 04
Archives of ophthalmology (Chicago, Ill. : 1960), 2010-06
The New England journal of medicine, 2016 Sep 15
Lancet (London, England), 2025 Jan 25
Stroke, 2023 Sep 07
Stroke, 2024 Jan 29
Arthritis & rheumatology (Hoboken, N.J.), 2021 Apr 26
Ophthalmology, 2016-06